Argus Investors Counsel’s AbbVie ABBV Stock Holding History

Argus Investors Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,359	Closed	-$247K	–	108
2024 Q1	$247K	Buy	+1,359	New	+$234K	0.15%	103
2019 Q1	–	Sell	-4,994	Closed	-$460K	–	71
2018 Q4	$460K	Buy	4,994 +722	+17%	+$63.5K	0.24%	52
2018 Q3	$404K	Buy	4,272 +616	+17%	+$58.4K	0.17%	55
2018 Q2	$339K	Buy	+3,656	New	+$357K	0.15%	55

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Argus Investors Counsel's ABBV Position: Q2 2024 in Review

Argus Investors Counsel sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 1,359 shares — an estimated $247K sold.

Argus Investors Counsel first reported a position in ABBV in Q2 2018 and held it in 4 quarters. The position peaked at $460K in Q4 2018. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Argus Investors Counsel reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Argus Investors Counsel sold 1,359 AbbVie shares in Q2 2024, an estimated $247K.
Argus Investors Counsel first reported a position in AbbVie in Q2 2018 and held it in 4 quarters.
Argus Investors Counsel's AbbVie position peaked at $460K in Q4 2018.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Argus Investors Counsel's 13F filing for Q2 2024, filed 19 Jul 2024.